Leerink Partners

Leerink Partners is a prominent investment banking firm founded in 1995 and headquartered in Boston, Massachusetts. Specializing in the healthcare sector, the firm offers a range of services including mergers and acquisitions, initial public offerings, debt financing transactions, and various equity offerings. With a focus on biopharmaceuticals, medical devices, diagnostics, and healthcare services, Leerink Partners leverages its extensive knowledge and experience to assist clients in achieving their strategic and capital market objectives. The firm partners with companies that are at the forefront of innovation in healthcare, helping them navigate complex financial landscapes.

Daniel B. Dubin

Vice Chairman, Global Co-Head of Investment Banking

17 past transactions

Odyssey Therapeutics

Series C in 2023
Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Kinnate Biopharma

Series C in 2020
Kinnate Biopharma Inc. is a biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating genomically defined cancers. Established in 2018 and headquartered in San Diego, California, the company focuses on precision oncology therapeutics, leveraging its expertise in structure-based drug discovery and translational research. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is advancing other preclinical candidates, including KIN003, which targets cancer-associated alterations in FGFR2 and FGFR3 genes, and a Cyclin-Dependent Kinase 12 inhibitor in the KIN004 program. Kinnate Biopharma is committed to developing targeted therapeutics for underserved patient populations, aiming to expand the reach of precision medicine in cancer treatment.

AlloVir

Series B in 2019
AlloVir is a biopharmaceutical company focused on developing allogeneic T-cell therapies to combat viral diseases. Its proprietary virus-specific T cell (VST) therapy platform enables the creation of off-the-shelf VSTs, designed to restore immunity in patients with T cell deficiencies at risk from life-threatening viral infections.

Fulcrum Therapeutics

Series B in 2018
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing novel therapies for patients with genetically defined diseases that have significant unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy, a rare condition characterized by progressive muscle wasting and disability. Another key candidate, FTX-6058, aims to upregulate fetal hemoglobin to treat sickle cell disease and beta-thalassemia. Fulcrum is also actively researching drug targets for other genetic disorders, including Duchenne muscular dystrophy and Friedreich ataxia, as well as neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma to explore biological targets in pulmonary disease and with MyoKardia to develop therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics continues to focus on improving patient outcomes in rare disease contexts.

Precision BioSciences

Series B in 2018
Precision BioSciences, founded in 2006, is a biotechnology company headquartered in Durham, North Carolina. It specializes in genome editing, developing therapeutic products using its proprietary ARCUS technology. The company focuses on creating allogeneic CAR T immunotherapies to treat cancers like acute lymphoblastic leukemia and non-hodgkin lymphoma, as well as genetic disorders.

FogPharma

Series B in 2018
FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Generation Bio

Series B in 2018
Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.

Avrobio

Series B in 2018
Avrobio is a clinical-stage biotechnology company focused on developing ex vivo lentiviral-based gene therapies to treat rare diseases with a single dose. Its pipeline includes AVR-RD-01 for Fabry disease, AVR-RD-02 for type 1 Gaucher disease, and AVR-RD-03 for Pompe disease.

Arcus Biosciences

Series C in 2017
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Replimune Group

Series B in 2017
Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.

Solid Biosciences

Series C in 2017
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Kyruus

Series C in 2015
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Translate Bio

Series B in 2015
Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Living Proof

Series C in 2013
Living Proof, Inc. is a hair care product manufacturer based in Cambridge, Massachusetts, founded in 2005. The company specializes in developing innovative hair care solutions that address various beauty challenges through advanced technology and science-backed formulas. Its product range includes shampoos, conditioners, styling treatments, nourishing creams, and a variety of sprays and serums designed to enhance hair health and appearance. Living Proof's formulations are suitable for all hair types, including color-treated hair, ensuring that consumers can achieve their desired results. The company distributes its products via its online store and through salons, retailers, and specialty beauty stores across several countries, including the United States, Canada, the United Kingdom, Australia, Singapore, and Thailand. In August 2008, the company changed its name from Andora, Inc. and has operated as a subsidiary of Unilever PLC since February 2017.

Humedica

Venture Round in 2012
Humedica is a clinical intelligence company that specializes in health analytics, offering tools designed for hospitals, physicians, and life sciences organizations. The company transforms unconnected data from various sources into actionable insights, enabling healthcare providers to make informed decisions. One of its key products, Humedica MinedShare, serves as a platform for clinical, operational, and financial benchmarking across the continuum of care, facilitating improved performance and outcomes in the healthcare sector. Through its innovative solutions, Humedica aims to enhance the quality of care and operational efficiency within the healthcare industry.

TESARO

Series B in 2011
Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Humedica

Series A in 2009
Humedica is a clinical intelligence company that specializes in health analytics, offering tools designed for hospitals, physicians, and life sciences organizations. The company transforms unconnected data from various sources into actionable insights, enabling healthcare providers to make informed decisions. One of its key products, Humedica MinedShare, serves as a platform for clinical, operational, and financial benchmarking across the continuum of care, facilitating improved performance and outcomes in the healthcare sector. Through its innovative solutions, Humedica aims to enhance the quality of care and operational efficiency within the healthcare industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.